Fineline Cube

Follow:
14691 Articles
Lifotronic Technology's H100Plus HbA1c Testing System Receives FDA 510(k) Clearance – Chinese IVD Company Gains U.S. Market Access for Diabetes Diagnostics
CompanyDrug

Lifotronic Technology’s H100Plus HbA1c Testing System Receives FDA 510(k) Clearance – Chinese IVD Company Gains U.S. Market Access for Diabetes Diagnostics

Hinova Pharmaceuticals' HP515 Phase IIa MASH Data Accepted as AASLD 2026 Late‑Breaking Abstract – THR‑β Agonist Achieves >50% Liver Fat Reduction With No SAEs
CompanyDrug

Hinova Pharmaceuticals’ HP515 Phase IIa MASH Data Accepted as AASLD 2026 Late‑Breaking Abstract – THR‑β Agonist Achieves >50% Liver Fat Reduction With No SAEs

Easton Pharmaceutical Wins NMPA Approval for Vitamin K1 Injection Pediatric Spec – Third Generic to Achieve Bioequivalence for Infant Hemorrhagic Disease Prevention
CompanyDrug

Easton Pharmaceutical Wins NMPA Approval for Vitamin K1 Injection Pediatric Spec – Third Generic to Achieve Bioequivalence for Infant Hemorrhagic Disease Prevention

Lepu Medical Subsidiary Secures FDA IND Clearance for MWN117 siRNA Targeting INHBE – Novel Obesity Drug Shows Synergy With GLP‑1 and Muscle Preservation in Primate Studies
CompanyDrug

Lepu Medical Subsidiary Secures FDA IND Clearance for MWN117 siRNA Targeting INHBE – Novel Obesity Drug Shows Synergy With GLP‑1 and Muscle Preservation in Primate Studies

CSPC Pharma Presents SYS6002 Phase I Data at IGCS 2026 – Nectin‑4 ADC Shows 35.9% ORR in Previously Treated Advanced Cervical Cancer; Phase III Underway
CompanyDrug

CSPC Pharma Presents SYS6002 Phase I Data at IGCS 2026 – Nectin‑4 ADC Shows 35.9% ORR in Previously Treated Advanced Cervical Cancer; Phase III Underway

Tong Ren Tang's Dingzhi Wan Receives Hong Kong Proprietary Chinese Medicine Registration – HKCMP Certificate Expands Neurological Wellness Product Line
CompanyDrug

Tong Ren Tang’s Dingzhi Wan Receives Hong Kong Proprietary Chinese Medicine Registration – HKCMP Certificate Expands Neurological Wellness Product Line

Sino Biopharmaceutical Completes Phase III Enrollment for TQC3721 Inhaled PDE3/4 Inhibitor in COPD – Dual‑Target Therapy Eyes First‑in‑China Approval
CompanyDrug

Sino Biopharmaceutical Completes Phase III Enrollment for TQC3721 Inhaled PDE3/4 Inhibitor in COPD – Dual‑Target Therapy Eyes First‑in‑China Approval

Huadong Medicine's Oral GLP‑1 Agonist HDM1002 Delivers Positive Phase III Results for Weight Management – Pre‑NDA Complete, China Marketing Application Imminent
CompanyDrug

Huadong Medicine’s Oral GLP‑1 Agonist HDM1002 Delivers Positive Phase III Results for Weight Management – Pre‑NDA Complete, China Marketing Application Imminent

Dezhan Healthcare Subsidiary Secures FDA IND Clearance for WYY026B Injection in Acute Ischemic Stroke – First‑in‑Class Neuroprotective Agent Advances to U.S. Clinical Trials
CompanyDrug

Dezhan Healthcare Subsidiary Secures FDA IND Clearance for WYY026B Injection in Acute Ischemic Stroke – First‑in‑Class Neuroprotective Agent Advances to U.S. Clinical Trials

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation
CompanyDrug

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

Hengrui Pharma's Fluzoparib Enters EMA Review for Prostate Cancer – First China‑Developed PARP Inhibitor Targets European mCRPC Market
CompanyDrug

Hengrui Pharma’s Fluzoparib Enters EMA Review for Prostate Cancer – First China‑Developed PARP Inhibitor Targets European mCRPC Market

Bayer's Finerenone Advances Toward FDA Approval for Non‑Diabetic CKD – sNDA Accepted Based on Phase III FIND‑CKD Data
CompanyDrug

Bayer’s Finerenone Advances Toward FDA Approval for Non‑Diabetic CKD – sNDA Accepted Based on Phase III FIND‑CKD Data